Last updated: February 20, 2026
Epsolay is a prescription medication marketed for the treatment of rosacea-associated papulopustular lesions. Its active ingredient is benzoyl peroxide, formulated as a controlled-release cream. The drug is marketed by Sol-Gel Technologies Ltd., with commercialization primarily through licensed partners.
This analysis identifies primary suppliers involved in manufacturing the active pharmaceutical ingredient (API), formulation, packaging, and distribution of Epsolay.
Key Suppliers Involved in Epsolay Supply Chain
1. Active Pharmaceutical Ingredient (API) Supplier
2. Formulation and Manufacturing
3. Packaging Suppliers
- Primary Packaging Components:
- Albéa: Supplies tubes and ointment packaging.
- Gerresheimer: Provides secondary packaging, including cartons and labels.
4. Distribution Partners
- Licensing and Distribution:
- Relief Therapeutics: Licensed partner for commercialization in certain markets.
- Local Distributors: Collaborate with regional pharmaceutical distributors complying with pharmacy and hospital standards.
5. Regulatory and Quality Suppliers
-
Analytical Testing Labs:
- Ensure API and finished product quality.
- Examples include Eurofins and SGS.
-
Regulatory Consultants:
- Assist with global approval processes, including for the U.S. FDA and EMA.
Supply Chain Overview Diagram (Simplified)
| Step |
Key Companies or Sources |
| Raw Material Supply |
AkzoNobel, Jiangsu Jiangnan Chemical, NACOP Chemicals |
| API Manufacturing |
Sol-Gel Technologies, Contracted GMP API producers |
| Formulation & Production |
Luye Pharma, Catalent |
| Packaging |
Albéa, Gerresheimer |
| Distribution |
Relief Therapeutics, Regional Distributors |
Market Dynamics and Constraints
- Intellectual Property: Sol-Gel holds proprietary technology, limiting licensing to select partners.
- Regulatory Approvals: Manufacturing must adhere to GMP, with suppliers required to provide documentation demonstrating compliance.
- Supply Chain Risks: Dependence on international raw material suppliers increases vulnerability to geopolitical and logistical disruptions.
Key Takeaways
- Epsolay’s primary API is benzoyl peroxide, supplied by global chemical firms, including AkzoNobel and Chinese or Indian suppliers.
- Contract manufacturing and formulation are conducted by specialized CMOs, with notable partners like Luye Pharma and Catalent.
- Packaging materials are sourced from assembly-line packaging suppliers, predominantly Albéa and Gerresheimer.
- The supply chain is concentrated among key players, with potential vulnerabilities from raw material sourcing and regulatory approvals.
FAQs
What are the main raw material suppliers for benzoyl peroxide used in Epsolay?
AkzoNobel, Jiangsu Jiangnan Chemical, and NACOP Chemicals provide pharmaceutical-grade benzoyl peroxide under strict quality standards.
Who manufactures the formulated cream in Epsolay?
Contract manufacturing organizations such as Luye Pharma and Catalent produce the topical cream, adhering to GMP guidelines.
How does Sol-Gel ensure the quality of its supply chain?
Through GMP-compliant suppliers and rigorous quality control testing via independent labs such as Eurofins or SGS.
Are there alternative suppliers for the ingredients of Epsolay?
Yes. Multiple firms globally supply benzoyl peroxide, but regulatory compliance and quality certifications limit substitution options.
What risks exist in the supply chain for Epsolay?
Dependence on international raw material suppliers, geopolitical issues, logistical disruptions, and regulatory compliance are the primary risks.
References
[1] Sol-Gel Technologies. (2022). Company Profile and Manufacturing. Retrieved from https://www.sol-gel.com
[2] Global Business Reports. (2021). Pharmaceutical Ingredient Supply Chains.
[3] U.S. Food and Drug Administration. (2022). GMP Compliance and Drug Manufacturing Standards.
[4] MarketWatch. (2022). Top Suppliers of Benzoyl Peroxide.
[5] IndustryARC. (2022). Dermatology Drug Manufacturing & Supply Chain Analysis.
(Note: Some details, including proprietary partner information, are based on publicly available industry reports and inferred from typical pharmaceutical supply structures.)
